Targeted combined endpoint improvement in patient and disease domains in atopic dermatitis (AD) among adults with moderate-to-severe AD treated with upadacitinib
Journal of the American Academy of Dermatology
; 87(3):AB208, 2022.
Article
in English
| EMBASE | ID: covidwho-2031398
ABSTRACT
Recommendations for a treat-to-target approach were recently developed to guide systemic therapy for disease control in adults with AD. Recommendations outlined criteria for a 3-month initial acceptable target goal reduction from baseline ≥1 on a 5-level Patient Global Impression of Severity (PGIS) scale and ≥1 specific disease domain target (≥50% improvement from baseline in Eczema Area and Severity Index [EASI-50];≥50% reduction in Scoring of AD [SCORAD-50];and a reduction from baseline in Worst Pruritus Numerical Rating Scale [WP-NRS] ≥3, Dermatology Life Quality Index [DLQI] ≥4, or Patient Oriented Eczema Measure [POEM] ≥4);and a 6-month optimal target goal PGIS ≤2 and ≥1 specific disease domain target (EASI-75 or EASI ≤7, SCORAD-75 or SCORAD ≤24, WP-NRS ≤4, DLQI ≤5, POEM ≤7). Achievement of these criteria with once-daily upadacitinib (15 mg and 30 mg) monotherapy was compared with placebo using integrated adult data from MU1 and MU2 trials and nonresponder imputation incorporating multiple imputation for missing values due to COVID-19. Greater proportions of patients treated with upadacitinib 15 mg;30 mg vs placebo (P <.001 for all) achieved the initial acceptable target goal at week 2 (78.9%;82.6% vs 25.0%) and week 16 (72.5%;80.2% vs 22.9%), and the optimal target goal at week 2 (52.8%;64.3% vs 6.3%) and week 16 (56.2%;70.1% vs 13.9%). These results suggest that once-daily oral upadacitinib (15 mg and 30 mg) may help improve standards of care in patients with moderate-to-severe AD by achieving 6-month target goals at 16 weeks and as early as 2 weeks for most patients.
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Language:
English
Journal:
Journal of the American Academy of Dermatology
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS